<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449889</url>
  </required_header>
  <id_info>
    <org_study_id>000191</org_study_id>
    <nct_id>NCT02449889</nct_id>
  </id_info>
  <brief_title>A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation</brief_title>
  <acronym>FASHION</acronym>
  <official_title>A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy and Safety of Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) for Triggering of Final Follicular Maturation in Women Undergoing Controlled Ovarian Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is investigating the efficacy and safety of highly purified human chorionic
      gonadotropin (HP-hCG) and recombinant human chorionic gonadotropin (rhCG) for triggering of
      final follicular maturation in women undergoing controlled ovarian stimulation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 9, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Oocytes Retrieved</measure>
    <time_frame>Approximately 36 hours after hCG administration</time_frame>
    <description>Oocyte retrieval took place 36 h (±2h) after hCG administration. At oocyte retrieval the number of oocytes retrieved was recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Metaphase II (MII) Oocytes</measure>
    <time_frame>Prior to insemination (within 6 hours after oocyte retrieval)</time_frame>
    <description>Only applicable for insemination using intracytoplasmic sperm injection (ICSI). The MII oocytes were counted prior to insemination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Fertilized (2 Pronuclei (2PN)) Oocytes</measure>
    <time_frame>One day after oocyte retrieval</time_frame>
    <description>Fertilization was assessed by counting the number of pronuclei, which was recorded as 0, 1, 2 or &gt;2. Correct fertilization was defined as oocytes with 2PN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive β Unit of Human Chorionic Gonadotropin (βhCG) Rate</measure>
    <time_frame>13-15 days after transfer</time_frame>
    <description>Defined as percentage of subjects with positive beta hCG. A positive β hCG was confirmed by a blood test obtained 13-15 days after transfer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>5-6 weeks after transfer</time_frame>
    <description>Defined as percentage of subjects with clinical pregnancy. Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events (AEs)</measure>
    <time_frame>AEs were collected from signing informed consent until end of trial visit = maximum period approximately 5 months. However, only TEAEs are presented</time_frame>
    <description>The number of treatment-emergent AEs (TEAEs) in each treatment group will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of AEs</measure>
    <time_frame>AEs were collected from signing informed consent until end of trial visit = maximum period approximately 5 months. However, only TEAEs are presented.</time_frame>
    <description>The intensity of an TEAE would be classified using the following 3-point scale: mild (awareness of signs or symptoms, but no disruption of usual activity), moderate (event sufficient to affect usual activity [disturbing]) or severe (inability to work or perform usual activities [unacceptable]).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>HP-hCG IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>highly purified human chorionic gonadotropin, intramuscularly (IM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HP-hCG SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>highly purified human chorionic gonadotropin, subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>recombinant human chorionic gonadotropin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>highly purified human chorionic gonadotropin</intervention_name>
    <arm_group_label>HP-hCG IM</arm_group_label>
    <arm_group_label>HP-hCG SC</arm_group_label>
    <other_name>CHORAPUR</other_name>
    <other_name>BREVACTID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human chorionic gonadotropin</intervention_name>
    <arm_group_label>rhCG</arm_group_label>
    <other_name>OVIDREL</other_name>
    <other_name>OVITRELLE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal females between the ages of 18 and 39 years

          -  Documented history of infertility

          -  Body mass index (BMI) between 17.5 and 32.0 kg/m2

          -  Regular menstrual cycles

        Exclusion Criteria:

          -  Known endometriosis stage III and IV

          -  Known polycystic ovarian syndrome (PCOS)

          -  History of recurrent miscarriage

          -  History of more than three previous controlled ovarian stimulation cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Ideia Fértil de Saúde Reproductive (there may be other sites in this country)</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <results_first_submitted>October 12, 2018</results_first_submitted>
  <results_first_submitted_qc>March 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2019</results_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02449889/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02449889/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 4 sites in Brazil randomized subjects to the trial.</recruitment_details>
      <pre_assignment_details>In total 245 subjects were screened. Of these, 69 were screening failures and 176 were randomized. All randomized subjects were exposed to investigational medicinal product (IMP).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HP-hCG IM</title>
          <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
        </group>
        <group group_id="P2">
          <title>HP-hCG SC</title>
          <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
        </group>
        <group group_id="P3">
          <title>rhCG SC</title>
          <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intention to treat (ITT) analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment. All relevant baseline data were summarized based on the ITT analysis set. The ITT analysis set included all 176 randomized subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>HP-hCG IM</title>
          <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
        </group>
        <group group_id="B2">
          <title>HP-hCG SC</title>
          <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
        </group>
        <group group_id="B3">
          <title>rhCG SC</title>
          <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35-37 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=38 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Oocytes Retrieved</title>
        <description>Oocyte retrieval took place 36 h (±2h) after hCG administration. At oocyte retrieval the number of oocytes retrieved was recorded.</description>
        <time_frame>Approximately 36 hours after hCG administration</time_frame>
        <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>HP-hCG IM</title>
            <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O2">
            <title>HP-hCG SC</title>
            <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O3">
            <title>rhCG SC</title>
            <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oocytes Retrieved</title>
          <description>Oocyte retrieval took place 36 h (±2h) after hCG administration. At oocyte retrieval the number of oocytes retrieved was recorded.</description>
          <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.</population>
          <units>Number of oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="4.6"/>
                    <measurement group_id="O2" value="7.3" spread="4.8"/>
                    <measurement group_id="O3" value="6.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mean number of oocytes retrieved for the treatment comparison of HP-hCG IM versus rhCG SC</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Treatment comparisons were done in a sequential manner. First non-inferiority (NI) was tested for HP-hCG IM compared to rhCG SC (lower limit of the 95% confidence interval (CI) &gt; -3.0). If NI was demonstrated, NI was also to be tested for HP-hCG SC compared to rhCG SC.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>ANOVA with treatment, stratum (&lt;10 or ≥10 follicles with a diameter ≥12 mm), and site as fixed factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mean number of oocytes retrieved for the treatment comparison of HP-hCG SC versus rhCG SC</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>As step 2 in the pre-specified sequential testing, NI was tested for HP-hCG SC compared to rhCG SC.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>ANOVA with treatment, stratum (&lt;10 or ≥10 follicles with a diameter ≥12 mm), and site as fixed factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Metaphase II (MII) Oocytes</title>
        <description>Only applicable for insemination using intracytoplasmic sperm injection (ICSI). The MII oocytes were counted prior to insemination.</description>
        <time_frame>Prior to insemination (within 6 hours after oocyte retrieval)</time_frame>
        <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.
Note that only subjects with ICSI were included in this analysis, i.e. 58 subjects in the HP-hCG IM group, 55 subjects in the HP-hCG SC group and 57 subjects in the rhCG SC group.</population>
        <group_list>
          <group group_id="O1">
            <title>HP-hCG IM</title>
            <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O2">
            <title>HP-hCG SC</title>
            <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O3">
            <title>rhCG SC</title>
            <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Metaphase II (MII) Oocytes</title>
          <description>Only applicable for insemination using intracytoplasmic sperm injection (ICSI). The MII oocytes were counted prior to insemination.</description>
          <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.
Note that only subjects with ICSI were included in this analysis, i.e. 58 subjects in the HP-hCG IM group, 55 subjects in the HP-hCG SC group and 57 subjects in the rhCG SC group.</population>
          <units>Number of MII oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="3.7"/>
                    <measurement group_id="O2" value="6.2" spread="3.5"/>
                    <measurement group_id="O3" value="5.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Number of MII oocytes retrieved for the treatment comparison of HP-hCG IM versus rhCG SC</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Pre-specified supportive endpoint analyzed in a similar manner as the primary endpoint.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>ANOVA with treatment, stratum (&lt;10 or ≥10 follicles with a diameter ≥12 mm), and site as fixed factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Number of Mll oocytes retrieved for the treatment comparison of HP-hCG SC versus rhCG SC</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Pre-specified supportive endpoint analyzed in a similar manner as the primary endpoint.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>ANOVA with treatment, stratum (&lt;10 or ≥10 follicles with a diameter ≥12 mm), and site as fixed factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Fertilized (2 Pronuclei (2PN)) Oocytes</title>
        <description>Fertilization was assessed by counting the number of pronuclei, which was recorded as 0, 1, 2 or &gt;2. Correct fertilization was defined as oocytes with 2PN.</description>
        <time_frame>One day after oocyte retrieval</time_frame>
        <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>HP-hCG IM</title>
            <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O2">
            <title>HP-hCG SC</title>
            <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O3">
            <title>rhCG SC</title>
            <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Fertilized (2 Pronuclei (2PN)) Oocytes</title>
          <description>Fertilization was assessed by counting the number of pronuclei, which was recorded as 0, 1, 2 or &gt;2. Correct fertilization was defined as oocytes with 2PN.</description>
          <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.</population>
          <units>Number of fertilized oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="3.3"/>
                    <measurement group_id="O2" value="4.7" spread="3.4"/>
                    <measurement group_id="O3" value="4.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Number of fertilized (2 pronuclei (2PN)) oocytes for the treatment comparison of HP-hCG IM versus rhCG SC</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Pre-specified supportive endpoint analyzed in a similar manner as the primary endpoint.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>ANOVA with treatment, stratum (&lt;10 or ≥10 follicles with a diameter ≥12 mm), and site as fixed factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Number of fertilized (2 pronuclei (2PN)) oocytes for the treatment comparison of HP-hCG SC versus rhCG SC.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Pre-specified supportive endpoint analyzed in a similar manner as the primary endpoint.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>ANOVA with treatment, stratum (&lt;10 or ≥10 follicles with a diameter ≥12 mm), and site as fixed factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive β Unit of Human Chorionic Gonadotropin (βhCG) Rate</title>
        <description>Defined as percentage of subjects with positive beta hCG. A positive β hCG was confirmed by a blood test obtained 13-15 days after transfer.</description>
        <time_frame>13-15 days after transfer</time_frame>
        <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>HP-hCG IM</title>
            <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O2">
            <title>HP-hCG SC</title>
            <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O3">
            <title>rhCG SC</title>
            <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
          </group>
        </group_list>
        <measure>
          <title>Positive β Unit of Human Chorionic Gonadotropin (βhCG) Rate</title>
          <description>Defined as percentage of subjects with positive beta hCG. A positive β hCG was confirmed by a blood test obtained 13-15 days after transfer.</description>
          <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="37.9"/>
                    <measurement group_id="O3" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy Rate</title>
        <description>Defined as percentage of subjects with clinical pregnancy. Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.</description>
        <time_frame>5-6 weeks after transfer</time_frame>
        <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>HP-hCG IM</title>
            <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O2">
            <title>HP-hCG SC</title>
            <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O3">
            <title>rhCG SC</title>
            <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate</title>
          <description>Defined as percentage of subjects with clinical pregnancy. Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.</description>
          <population>The ITT analysis set was defined as all randomized subjects. Subjects were analyzed according to planned (randomized) treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6"/>
                    <measurement group_id="O2" value="27.6"/>
                    <measurement group_id="O3" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events (AEs)</title>
        <description>The number of treatment-emergent AEs (TEAEs) in each treatment group will be presented.</description>
        <time_frame>AEs were collected from signing informed consent until end of trial visit = maximum period approximately 5 months. However, only TEAEs are presented</time_frame>
        <population>Safety was summarized based on the safety analysis set.The safety analysis set included all 176 subjects. Subjects were analyzed according to their actual treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>HP-hCG IM</title>
            <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O2">
            <title>HP-hCG SC</title>
            <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O3">
            <title>rhCG SC</title>
            <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events (AEs)</title>
          <description>The number of treatment-emergent AEs (TEAEs) in each treatment group will be presented.</description>
          <population>Safety was summarized based on the safety analysis set.The safety analysis set included all 176 subjects. Subjects were analyzed according to their actual treatment.</population>
          <units>Number of AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of AEs</title>
        <description>The intensity of an TEAE would be classified using the following 3-point scale: mild (awareness of signs or symptoms, but no disruption of usual activity), moderate (event sufficient to affect usual activity [disturbing]) or severe (inability to work or perform usual activities [unacceptable]).</description>
        <time_frame>AEs were collected from signing informed consent until end of trial visit = maximum period approximately 5 months. However, only TEAEs are presented.</time_frame>
        <population>Safety was summarized based on the safety analysis set.The safety analysis set included all 176 subjects. Subjects were analyzed according to their actual treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>HP-hCG IM</title>
            <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O2">
            <title>HP-hCG SC</title>
            <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
          </group>
          <group group_id="O3">
            <title>rhCG SC</title>
            <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of AEs</title>
          <description>The intensity of an TEAE would be classified using the following 3-point scale: mild (awareness of signs or symptoms, but no disruption of usual activity), moderate (event sufficient to affect usual activity [disturbing]) or severe (inability to work or perform usual activities [unacceptable]).</description>
          <population>Safety was summarized based on the safety analysis set.The safety analysis set included all 176 subjects. Subjects were analyzed according to their actual treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any mild AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any moderate AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from signing informed consent until end of trial visit = maximum period approximately 5 months.</time_frame>
      <desc>AEs with onset after IMP administration were considered treatment-emergent and are presented for the safety analysis set.</desc>
      <group_list>
        <group group_id="E1">
          <title>HP-hCG IM</title>
          <description>Highly purified human chorionic gonadotropin 5000 international units (IU), intramuscularly (IM)
Highly purified human chorionic gonadotropin</description>
        </group>
        <group group_id="E2">
          <title>HP-hCG SC</title>
          <description>Highly purified human chorionic gonadotropin, 5000 IU subcutaneously (SC)
Highly purified human chorionic gonadotropin</description>
        </group>
        <group group_id="E3">
          <title>rhCG</title>
          <description>Recombinant human chorionic gonadotropin 250 µg SC
Recombinant human chorionic gonadotropin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Biochemical pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemorrhage in pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vanishing twin syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the Principal Investigator (PI) is that Sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the Sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Sponsor to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Compliance</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

